Report: Race for Proteomics Knowledge Spurs Investment and Partnerships

NEW YORK, Sept. 30, 2014 /PRNewswire/ -- Proteomics is a focus point for investment and collaboration, according to a new report from Kalorama Information.  The healthcare market research publisher said that over 100 deals had occurred in proteomics in the past two years.  The activity ranges from investments and IPOs, to agreements between private proteomic companies and academic institutions, to deals between pharma and biotech companies with novel proteomics innovator companies.  Kalorama observed the industry in its report, Proteomics Markets for Research and IVD Applications.

The report can be obtained at: http://www.kaloramainformation.com/redirect.asp?progid=86681&productid=8359865.

Proteomics is the study of proteins, including the study of the structure and function of proteins.  This includes the study of which proteins are expressed, when and where they are expressed, structure of proteins, roles of proteins, and interactions of proteins.  Many drug targets are proteins, and proteomics is an important tool for identification and characterization of novel drug targets.  In addition, proteomics is an important tool for the identification of novel biomarkers and biomarker panels to meet unmet needs for diagnosis of diseases and determining the best treatment for individual patients (personalized medicine).

"There's a lot of interest in identification and validation of novel biomarkers that may represent potential drug targets or may lead to novel diagnostic tests," said Bruce Carlson, Publisher of Kalorama Information.  "Researchers are looking to proteomics for these discoveries."

The following activities represent just a partial list of significant proteomics events detailed in the report:   

• Thermo Fisher Scientific and Nuclea Biotechnologies will develop multiplexed mass spectometry-based research methods that Nuclea will use to analyze donor plasma samples from Boston-based diabetes research collaborations.
• BG Medicine and Kindstar Diagnostics announced an agreement under which Kindstar will offer galectin-3 testing services in China.
• AYOXXA Biosystems GmbH - announced that the company had completed a €9.0 million series B financing in June 2014. investors in this round included several private investors from the US and Europe, including AYOXXA employees and two of Qiagen's founders.
• Biocartis and Invetech announced a collaboration agreement to support development and manufacture of Evalution™, Biocartis' advanced multiplex platform for analysis of a broad range of protein and nucleic acid-based biomarkers. Invetech provides in instrument development, custom automation, and contract manufacturing.
• SQI Diagnostics announced that the company had closed a previously announced public offering of 8 million units at a price of CDN $0.50 per unit, raising CDN $4.2 million.
• Integrated Diagnostics announced that the company had raised $30.25 million from the closing of its Series B and $17 million in non-dilutive debt financing provided by Life Sciences Alternative Funding LLC (LSAF). This financing round was led by Baird Capital and joined by Indi's existing investors, InterWest Partners and the Wellcome Trust.

Kalorama's report, Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) contains breakouts of the market by type of technology used and application.  It profiles companies and surveys partnerships and deals related to proteomics.  Find this report in addition to other industry leading research from Kalorama at: http://www.kaloramainformation.com/.

About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.

Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com

Logo - http://photos.prnewswire.com/prnh/20140801/132634

SOURCE Kalorama Information